Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography

Cancer

Volumn 116, Issue 19, 2010, Pages 4487-4494

  Patnana, Srikrishna V ^a   Murthy, Santosh B ^a   Xiao, Lianchun ^a   Rohren, Eric ^a   Hofstetter, Wayne L ^a   Swisher, Stephen G ^a   Liao, Zhongxing ^a   Lee, Jeffrey H ^a   Bhutani, Manoop S ^a   Macapinlac, Homer A ^a   Wang, Xuemei ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemoradiation; Esophageal cancer; Poor prognostic group; Positron emission tomography evaluation; Surgery

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUOROPYRIMIDINE; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; EVENT FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMALLY INVASIVE SURGERY; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; COMPARATIVE STUDY; DIAGNOSTIC USE; ESOPHAGEAL NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; STOMACH NEOPLASMS;

ADULT; AGED; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 77957555544     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25431     Document Type: Article

References (43)

1. Cancer Research UK. Oesophageal cancer - UK incidence statistics. Available at: http://info.cancerresearchuk.org/cancerstats/types/oesophagus/ incidence/. Accessed October 14, 2008.
2. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100:1184-1187.
3. Ajani JA, Winter K, Komaki R, et al. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol. 2008;26:4551-4556.
4. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term followup of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281:1623-1627. (Pubitemid 29211772)
5. Suntharalingam M, Moughan J, Coia LR, et al. Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus. J Clin Oncol. 2005;23:2325-2331.
6. Suntharalingam M, Moughan J, Coia LR, et al. The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 Patterns of Care Study. Int J Radiat Oncol Biol Phys. 2003;56:981-987.
7. Pereira B, Gourgou-Bourgade S, Azria D, Ychou M. Neoadjuvant chemoradiotherapy in esophageal cancer: is it still the question? J Clin Oncol. 2008;26:5133-5134.
8. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086-1092.
9. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305-313. (Pubitemid 32112841)
10. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161-167.
11. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462-467.
12. Rice TW, Blackstone EH, Rybicki LA, et al. Refining esophageal cancer staging. J Thorac Cardiovasc Surg. 2003;125:1103-1113.
13. Sasako M, Sano T, Yamamoto S, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol. 2006;7:644-651.
14. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature. 2008;452:553-563.
15. Sawyers CL. The cancer biomarker problem. Nature. 2008;452:548-552.
16. van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature. 2008;452:564-570.
17. Luthra MG, Ajani JA, Izzo J, et al. Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res. 2007;13:912-919.
18. Luthra R, Wu TT, Luthra MG, et al. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol. 2006;24:259-267.
19. Hildebrandt MAT, Yang H, Hung MC, et al. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcome in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol. 2009;27:857-871.
20. Wu X, Gu J, Wu TT, et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol. 2006;24:3789-3798.
21. Ott K, Herrmann K, Lordick F, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res. 2008;14:2012-2018.
22. Ott K, Weber W, Siewert JR. The importance of PET in the diagnosis and response evaluation of esophageal cancer. Dis Esophagus. 2006;19:433-442.
23. Wieder HA, Geinitz H, Rosenberg R, et al. PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:878-883.
24. Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000;18:3202-3210.
25. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24:4692-4698.
26. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058-3065.
27. Wieder HA, Brucher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004;22:900-908.
28. Erasmus JJ, Munden RF, Truong MT, et al. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol. 2006;1:478-486.
29. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797-805.
30. Swisher SG, Erasmus J, Maish M, et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004;101:1776-1785.
31. Brucher BL, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg. 2001;233:300-309. (Pubitemid 32187807)
32. Brucher BL, Swisher SG, Königsrainer I, et al. Response to preoperative therapy in upper gastrointestinal cancers. Ann Surg Oncol. 2009;16:878-886.
33. Murthy SB, Patnana SV, Xiao L, et al. The standardized uptake value of 18-fluoro-deoxy glucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology. In press.
34. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457-1459.
35. Kelloff GJ, Sullivan DM, Wilson W, et al. FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol. 2007;14:330-339.
36. Shankar LK, Sullivan DC. PET/CT in cancer patient management. Commentary. J Nucl Med. 2007;48(suppl 1):1S.
37. Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006;47:1059-1066.
38. Mantel N. Evaluation of survival data and two new rank order statistics arising in ints consideration. Cancer Chemother Rep. 1996;60:163-170.
39. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187-220.
40. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
41. Rice TW, Rusch VW, Apperson-Hansen C, et al. Worldwide esophageal cancer collaboration. Dis Esophagus. 2009;22:1-8.
42. Siewert JR, Sendler A, Stein HJ. Esophageal cancer: surgical approach. In: Markman M, ed. Atlas of Cancer. Philadelphia: Current Medicine Group of Springer Science; 2007:211-220.
43. Ajani JA, Barthel JS, Bekaii-Saab T, et al. Esophageal cancer. J Natl Compr Canc Netw. 2008;6:818-849.